Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Merck & Co. Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Merck & Co. Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio shows initial fluctuations around 2.5 to 2.7 between March 2021 and December 2021. Subsequently, it experienced a gradual upward trend, peaking near 2.89 in September and December 2022, indicating improved efficiency in utilizing fixed assets to generate sales during this period. However, from early 2023 onwards, the ratio exhibits a slow but steady decline, stabilizing around 2.6 towards the end of 2024, before decreasing slightly again into mid-2025. This suggests that while fixed asset utilization improved temporarily, efficiency gains have not been consistently sustained over the longer term.
- Total Asset Turnover
- The total asset turnover ratio begins at a moderate level around 0.51 to 0.52 in early 2021. It then declined to a low of approximately 0.46 by the first quarter of 2022, signaling a period of decreased efficiency in using total assets to generate revenue. Thereafter, the ratio recovered steadily throughout 2022 and 2023, reaching a peak near 0.58 by the end of 2023. This upward trend reflects an overall enhancement in asset utilization. In 2024 and early 2025, the ratio slightly decreased but remained relatively stable around 0.54 to 0.56, indicating a maintained level of efficiency close to the recent peak.
- Equity Turnover
- The equity turnover ratio demonstrates a notable downward trend from early 2021 through late 2021, falling from 1.9 to around 1.28. This decline suggests reduced effectiveness in generating sales from shareholder equity during this period. After reaching this low, the ratio fluctuated mildly but generally stabilized between approximately 1.3 and 1.6 in 2022 and 2023. Some intervals exhibit minor rebounds, such as mid-2023 when it peaked around 1.6, followed by subsequent decreases. Toward 2024 and into mid-2025, the ratio gradually declined again to about 1.3, implying a resurgence of reduced turnover of equity in sales generation towards the end of the observed period.
Net Fixed Asset Turnover
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Sales | |||||||||||||||||||||||||||||
Property, plant and equipment, at cost, net of accumulated depreciation | |||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||
Net fixed asset turnover1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Net fixed asset turnover
= (SalesQ2 2025
+ SalesQ1 2025
+ SalesQ4 2024
+ SalesQ3 2024)
÷ Property, plant and equipment, at cost, net of accumulated depreciation
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Sales
- Sales figures demonstrate notable fluctuations across the observed quarters. Initially, sales decreased from US$12,057 million in March 2020 to US$10,872 million in June 2020, followed by a recovery to US$12,551 million in September 2020 and a stabilization at approximately US$12,500 million by December 2020. The first half of 2021 shows a mixed pattern with a decline to US$10,627 million in March followed by a rebound to US$11,402 million in June. The remainder of 2021 reflected steady growth, peaking at US$13,521 million by year-end.
- From 2022 onwards, sales exhibit a strong upward trend, reaching a maximum of US$16,657 million in September 2024 before experiencing a minor decline toward the end of the period. The average sales level in this later period is substantially higher than in 2020 and 2021, indicating overall growth in the business volume despite some short-term volatility.
- Property, Plant, and Equipment, at Cost, Net of Accumulated Depreciation
- This asset category shows a consistent upward trend throughout the evaluated period. The net book value increased from US$15,269 million in March 2020 to US$25,236 million by June 2025. Growth was steady without any apparent periods of decline, reflecting ongoing investment or capital expenditures in fixed assets.
- The substantial increase in property, plant, and equipment reflects expansion or replacement activities, suggesting a commitment to maintaining or enhancing operational capacity over time.
- Net Fixed Asset Turnover Ratio
- The net fixed asset turnover ratio, reported from September 2020 onward, reveals a relatively stable but slightly declining trend. Starting at 2.67 in September 2020, the ratio fluctuates moderately, ranging roughly between 2.52 and 2.89 until the latest data point at 2.52 in June 2025.
- This ratio measures the efficiency in generating sales from fixed asset investment. The gradual decline over the years indicates that sales growth has not kept pace with the increasing investment in fixed assets, implying a potential decrease in asset utilization efficiency.
- Overall Analysis
- In summary, sales show variability with an overall upward trend in recent years, while fixed assets steadily increase, reflecting ongoing capital investment. The declining net fixed asset turnover suggests that asset efficiency may be deteriorating slightly as the company expands its asset base more rapidly than sales grow. This could warrant further investigation into asset management and operational productivity.
Total Asset Turnover
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Sales | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||
Total asset turnover1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Total Asset Turnover, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Total asset turnover
= (SalesQ2 2025
+ SalesQ1 2025
+ SalesQ4 2024
+ SalesQ3 2024)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The quarterly financial data reveals several noteworthy trends over the reported periods. Sales figures display a fluctuating but generally upward trajectory with some periods of decline. Initially, sales decreased from 12,057 million in the first quarter of 2020 to 10,627 million in the first quarter of 2021. Subsequently, sales rose steadily, peaking at 16,657 million in the third quarter of 2024 before slightly retreating to 15,806 million by the fourth quarter of 2025.
Total assets exhibit growth until late 2022, increasing from 84,913 million in the first quarter of 2020 to a peak of 117,532 million in the second quarter of 2024. After this peak, assets showed minor fluctuations but remained relatively stable near this high level through the end of the period, ending at 117,523 million in the fourth quarter of 2025.
The total asset turnover ratio, available from the third quarter of 2020 onward, demonstrates a moderate but consistent improvement over the observed timeframe. Starting around 0.51-0.52 in 2020 and early 2021, the ratio gradually increased to approximately 0.56-0.58 by 2024, indicating enhanced efficiency in utilizing assets to generate sales.
- Sales Trend
- Sales experienced volatility with an initial decline through early 2021, followed by a solid upward trend peaking in mid-2024. The latter quarters showed some slight decreases but sales remained well above earlier period lows.
- Total Assets Growth
- Total assets increased substantially from 2020 through 2024, nearly doubling over the period. Stability at elevated levels was observed starting in late 2024, suggesting a consolidation phase or balanced asset management.
- Asset Turnover Efficiency
- The upward trend in total asset turnover ratio points to improving operational efficiency. The company appears to be generating more sales per unit of assets over time, potentially reflecting better asset utilization or improved sales performance relative to asset base.
Overall, the data suggests a period of growth and efficiency improvement following early challenges. Increasing sales and asset bases combined with improving turnover ratios indicate positive operational momentum. The slight recent declines in sales and stabilization of assets could warrant monitoring to ensure sustained performance gains.
Equity Turnover
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
Sales | |||||||||||||||||||||||||||||
Total Merck & Co., Inc. stockholders’ equity | |||||||||||||||||||||||||||||
Long-term Activity Ratio | |||||||||||||||||||||||||||||
Equity turnover1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Equity Turnover, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Equity turnover
= (SalesQ2 2025
+ SalesQ1 2025
+ SalesQ4 2024
+ SalesQ3 2024)
÷ Total Merck & Co., Inc. stockholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Sales Trends
- Sales exhibit notable fluctuations across the reported quarters. Initially, sales decline from 12,057 million USD in March 2020 to 10,627 million USD in March 2021. Subsequently, a recovery pattern emerges with sales increasing to 15,901 million USD by March 2022. Following this peak, sales fluctuate moderately, reaching 15,806 million USD by June 2025. This pattern suggests some volatility possibly linked to external market factors or internal business dynamics but generally reflects a recovery and growth phase after an initial downturn.
- Stockholders' Equity
- Total stockholders’ equity demonstrates a general upward trend across the periods with intermittent decreases. Starting at 26,205 million USD in March 2020, equity rises consistently to reach 46,993 million USD by June 2025. Notably, there is a dip to 38,693 million USD in June 2023 and again to 37,581 million USD in December 2023, indicating possible equity adjustments or impacts from extraordinary items during this time. Overall, the long-term movement reflects strengthening equity base and capitalization.
- Equity Turnover
- Equity turnover ratios are available for periods beginning September 2020 and exhibit a general decreasing trend initially. The ratio declines from 1.9 in September 2020 to a low of 1.24 in June 2023, which may indicate decreasing efficiency in generating sales from equity during this interval. However, after June 2023, there is a recovery in equity turnover, climbing to 1.6 in March 2024, followed by slight decreases but maintaining values above 1.3 by June 2025. This rebound suggests improved utilization of equity for sales generation after mid-2023.
- Overall Financial Insights
- The sales recovery and general growth in stockholders’ equity, coupled with the rebound in equity turnover ratios, indicate a strengthening financial position post-2021. The intermittent declines and fluctuations across the measured variables may reflect strategic adjustments, market conditions, or one-time events affecting operational efficiency and capital structure. The upward trend in equity, alongside increased sales volumes, suggests a potentially enhanced capacity for generating returns on equity going forward.